Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Completed · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine together with docetaxel works in treating patients with metastatic prostate cancer.
Key facts
- Study ID
- NCT00258284
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 30
- Starts
- 2003-08-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2014-03-06
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.